Wall Street Zen Upgrades vTv Therapeutics (NASDAQ:VTVT) to “Hold”

vTv Therapeutics (NASDAQ:VTVT) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Other analysts also recently issued reports about the stock. Lifesci Capital upgraded shares of vTv Therapeutics to a “strong-buy” rating in a report on Wednesday, September 2nd. Zacks Research raised shares of vTv Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. Weiss Ratings downgraded shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. BTIG Research restated a “buy” rating and set a $57.00 price objective on shares of vTv Therapeutics in a research report on Wednesday, October 14th. Finally, HC Wainwright reduced their target price on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, vTv Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.83.

vTv Therapeutics Price Performance

Shares of VTVT opened at $21.03 on Friday. vTv Therapeutics has a 1 year low of $20.56 and a 1 year high of $44.00. The company has a 50 day simple moving average of $29.22 and a two-hundred day simple moving average of $33.23. The firm has a market cap of $82.86 million, a P/E ratio of -22.86 and a beta of 0.29.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Thursday, November 5th. The biotechnology company reported ($0.94) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.15. On average, sell-side analysts anticipate that vTv Therapeutics will post -2.35 earnings per share for the current year.

Institutional Investors Weigh In On vTv Therapeutics

A hedge fund recently raised its position in vTv Therapeutics stock. China Universal Asset Management Co. Ltd. boosted its holdings in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) by 114.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,360 shares of the biotechnology company’s stock after purchasing an additional 2,860 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in vTv Therapeutics were worth $161,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer’s disease.